PharmaFocus Today – Page 27 – media

The company’s Phase III clinical study of the nine-valent HPV vaccine is ongoing.

an investor asked on the investor interaction platform: When is the company’s nine-valent vaccine expected to be launched? What is its current stage? What is the annual production capacity of the company’s production line? Watson Bio(300142.SZ) stated on the investor interaction platform on September 24 that the company’s related work on the Phase III clinical study of the nine-valent HPV vaccine is ongoing. If there is any substantial and phased progress in the research and development of the company’s vaccine, the company will disclose it in a timely manner. Please pay attention to the relevant information disclosed by the company for subsequent progress. Source；https://finance.eastmoney.com/a/202509243522306220.html
- Source: drugdu
- 159
- October 2, 2025
The company has acquired a controlling stake in Chenan Bio by increasing capital this year.

SecuritiesDaily News Zhifei BiologyWhen answering investors’ questions on the interactive platform on September 26, it was stated that the company had achieved controlling stake in Chenan Bio through capital increase this year, and the company’s business had extended from vaccines to metabolic diseases. Source：https://finance.eastmoney.com/a/202509263524977168.html
- Source: drugdu
- 90
- October 2, 2025
CKBA Cream, a subsidiary of the holding company, has been approved for clinical trials for rosacea.

Taienkang announced that its controlling subsidiary, Broad Venture Park, has received a “Notice of Approval for Drug Clinical Trial” from the National Medical Products Administration (NMPA), authorizing the conduct of a Phase II/III seamless adaptive clinical trial of CKBA Cream for the rosacea indication. CKBA Cream is a topical preparation independently developed by Broad Venture Park and is a Category 1 innovative chemical drug. To date, no Category 1 innovative drug for the treatment of rosacea has been approved for marketing in China . Tainkang’s innovative drug has been approved for clinical trials and is expected to fill the treatment gap for rosacea indications in China . If clinical trials can prove its efficacy, the market potential is considerable. Source：https://www.stcn.com/article/detail/3358450.html
- Source: drugdu
- 85
- October 2, 2025
Another indication for ADC bispecific antibody Iza-Bren has been included in the Breakthrough Therapy List

Baili Tianheng issued an announcement stating that the company’s independently developed iza-bren (EGFR×HER3 dual-antibody ADC), the world’s first, new concept and the only one to enter the Phase III clinical stage, is used for patients with unresectable locally advanced or metastatic urothelial carcinoma who have failed previous treatment with platinum-containing chemotherapy and PD-1/PD-L1 inhibitors. It has been included in the list of breakthrough therapies by the Drug Review Center of the National Medical Products Administration. To date, seven indications of Iza-bren have been included in the list of breakthrough therapies by the Center for Drug Evaluation, and one indication has been granted breakthrough therapy designation by the U.S. Food and Drug Administration. The National Medical Products Administration’s Center for Drug Evaluation prioritizes resources for drugs included in the Breakthrough Therapy designation, strengthening guidance and promoting drug development. Baili Tianheng’s Iza-bren has been designated a Breakthrough Therapy, which is expected to ...
- Source: drugdu
- 119
- October 2, 2025
Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development! Losing 2.8 billion yuan in three years, causing a sharp drop in monetary funds

On the evening of September 29th, Luoxin Pharmaceutical (002793) announced that it plans to raise no more than 842 million yuan for innovative drug research and development projects, raw material drug expansion and freeze-drying workshop technology renovation projects, and to supplement working capital. According to the data, Luoxin Pharmaceutical is mainly engaged in the research, development, production and sales of pharmaceutical products, focusing on digestion, respiration, anti-tumor and other advantageous fields. Its products are mainly chemical preparations, chemical raw materials, and traditional Chinese patent medicines and simple preparations. The company was listed on the Shenzhen Stock Exchange in April 2016. Luoxin Pharmaceutical stated that in order to strengthen the company’s innovative drug product layout and improve the market competitiveness of innovative drug products, the innovative drug research and development project in this fundraising investment project will focus on the Phase II and III clinical studies of LX22001 for injection to ...
- Source: drugdu
- 125
- October 2, 2025
Changchun High tech goes public in Hong Kong, ‘Hormone Grass’ accelerates search for breakthrough path

Changchun High tech, which once dominated the capital market with growth hormone, is accelerating its plan to go public in Hong Kong after experiencing a performance slump, attempting to find a new way out in the midst of difficulties. On September 29th, according to the Hong Kong Stock Exchange, Changchun High Tech Industry (Group) Co., Ltd. (referred to as “Changchun High Tech”) from Changchun, Jilin submitted a prospectus to the Hong Kong Stock Exchange, intending to be listed on the main board of Hong Kong. Changchun High Tech was listed on the Shenzhen Stock Exchange on December 18, 1996, and as of the close of trading on September 29, 2025, its total market value was RMB 52.583 billion. This marks the official launch of the “A+H” dual platform listing journey for the growth hormone Mao, which once created a “myth” in the A-share market. A pharmaceutical industry analyst from a ...
- Source: drugdu
- 296
- October 2, 2025
Researchers design factor IX variants for short- and long-term Hemophilia B management

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, results from a deficiency in coagulation factor IX (FIX), which can lead to prolonged bleeding after injuries or surgery. Thus, patients with hemophilia B are often treated with recombinant FIX as a replacement therapy, and while this approach has improved treatment for hemophilia B, the plasma half-lives of the approved products are only about 3-4 days, and frequent injections are needed. Consequently, there is a pressing need for recombinant FIX products with enhanced plasma half-life that allows less frequent dosing. In the current study, the laboratories of Professor Jan Terje Andersen at the University of Oslo and Alessio Branchini/Mirko Pinotti at the University of Ferrara (Italy) present design and characterization of long-acting human albumin-fused FIX variants, each exhibiting unique pharmacokinetic properties. The ...
- Source: drugdu
- 90
- September 30, 2025
FDA Approves Opzelura for Atopic Dermatitis in Children

By Lori Solomon HealthDay ReporterMONDAY, Sept. 29, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). The approval is the first topical Janus kinase (JAK) inhibitor for the short-term, noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised children (age 2 years and older) whose disease is not well controlled with topical prescription therapies or when topical therapies are not recommended. The approval is based on results from the phase 3 TRuE-AD3 trial, which evaluated the safety and efficacy of Opzelura cream in children ages 2 to <12 years with AD. The primary end point was met, with significantly more patients treated with Opzelura achieving Investigator’s Global Assessment-treatment success versus patients treated with vehicle control cream. The trial also met the secondary end point of more Opzelura-treated patients demonstrating ≥75 percent improvement ...
- Source: drugdu
- 121
- September 30, 2025
Lunan Pharmaceutical’s blockbuster first generic drug approved, ushering in changes in the allergy market

Recently, the official website of the State Food and Drug Administration announced that the orally disintegrating tablets of Bilastine, which were submitted by Shandong Xinshidai Pharmaceutical, a subsidiary of Lunan Pharmaceutical Group, under the Class 3 chemical drug registration classification, have been approved for marketing and are deemed to have passed the generic drug quality and efficacy consistency evaluation. They are used for the symptomatic treatment of urticaria in adults and adolescents (12 years and above). The original product, Bilastine, was developed by FAES Pharmaceuticals of Spain and first marketed in the EU in August 2010. In June 2023, Menarini’s Bilastine tablets were approved for marketing in China. In 2024, Jiangsu Huayang Pharmaceutical secured the first domestic generic version of Bilastine tablets. This time, Lunan Pharmaceutical’s Bilastine orally disintegrating tablets were approved for marketing, marking the first domestic generic version of this dosage form and the first to pass review. ...
- Source: drugdu
- 102
- September 30, 2025
A subsidiary received approval for clinical trials of HRS-2129 tablets. Currently, no drug with the same target has been approved for marketing in China.

According to the AI news of the China Business Network, on September 29, Hengrui Medicine (600276.SH) announced that its subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration for HRS-2129 tablets, agreeing to conduct clinical trials for the indications of adult diabetic peripheral neuropathy pain and adult osteoarthritis pain. HRS-2129 tablets are intended for the treatment of acute and chronic pain. Currently, no drugs with the same target have been approved for marketing in China. As of now, the cumulative R&D investment in this project is approximately 112 million yuan. According to relevant laws and regulations, after obtaining the drug clinical trial approval notice, the drug must still conduct clinical trials and be reviewed and approved by the National Medical Products Administration before it can be produced and marketed. https://finance.eastmoney.com/a/202509293526362066.html
- Source: drugdu
- 160
- September 30, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.